Manage cutaneous adverse effects induced by diabetes medications or devices by removing the offending agent and choosing appropriate treatment
- 8 Downloads
Numerous cutaneous adverse effects (CAEs) have been reported with glucose-lowering medications (e.g. insulin, dipeptidyl peptidase 4 inhibitors and sulfonylureas) and medical devices (e.g. continuous subcutaneous insulin infusion and continuous glucose monitoring) used in the management of diabetes. Notable CAEs include angioedema, autoimmune blistering diseases, contact dermatitis, Stevens-Johnson syndrome and worsening blood glucose control. While some of CAEs are common and others rare, it is important for healthcare providers to be aware of the potential culprits and their associated CAEs, as well as effective methods to prevent and/or treat such effects.
Compliance with ethical standards
Conflict of interest
The article was adapted from the American Journal of Clinical Dermatology 2019; 20(1): 97–114 by employees of Adis International Ltd./Springer Nature, who are responsible for the article content and declare no conflicts of interest.
The preparation of this review was not supported by any external funding.
- 1.World Health Organization. Global report on diabetes. Geneva: WHO Press; 2016.Google Scholar
- 2.Rosen J, Yosipovitch G. Skin manifestations of diabetes mellitus. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2018.Google Scholar
- 10.Gibbs JP, Fredrickson J, Barbee T, et al. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J Clin Pharmacol. 2012;52(10):1494–505.PubMedCrossRefGoogle Scholar